Biogen Idec Business Development Plan Includes Small Molecules For Oncology
This article was originally published in The Pink Sheet Daily
Executive Summary
The company expects the bulk of expenditures from a $200 mil. business development plan will go toward up-front milestones and new clinical costs for in-licensed drugs.